Q-omics provides the consensus-scored GRAMD4P3 profile across patient tissues and cancer cell-line models. GRAMD4P3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GRAMD4P3 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, GRAMD4P3 RNA expression shows 6,536 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, KIRC, and STAD as cancer lineages where GRAMD4P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRAMD4P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRAMD4P3 survival associations across molecular data types. GRAMD4P3 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRAMD4P3 RNA expression–survival associations across cancer types. High GRAMD4P3 expression shows unfavorable associations in LIHC, THCA, DLBC, KIRP and KICH, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify HNSC as the clearest survival context for GRAMD4P3 RNA expression.
This table summarizes GRAMD4P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GRAMD4P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRAMD4P3 shows higher tumor expression in KIRC, BLCA, BRCA, LUAD, LIHC and PRAD. The KIRC box plot shows higher GRAMD4P3 RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p < 0.001).
This table shows molecular features associated with GRAMD4P3 in patient tissues and cancer cell lines. In patient samples, GRAMD4P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
